Expression of IL-17 with tumor budding as a prognostic marker in oral squamous cell carcinoma

American Journal of Translational Research

Gupta¹  Shijian Zhang²  Xudong Wang³  An⁴  Xin Fang⁵ 

[1] Department of Dentistry, Government Medical College and Hospital, Chandigarh, India;Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth Peoples Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China;National Clinical Research Center for Oral Diseases, Shanghai, China;Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China;Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institute, Stockholm 17177, Sweden

关键词: IL-17;    tumor budding;    oral squamous cell carcinoma;    tumor invasion front;    prognosis;   

DOI  :  

学科分类：医学（综合）

来源: e-Century Publishing Corporation

【 摘 要 】

We evaluated the relationship between IL-17 expression and tumor budding in the oral squamous cell carcinoma (OSCC) tumor invasion front (TIF). We also analyzed the correlation between OSCC prognosis and the co-expression of IL-17 and tumor budding. We obtained tumor tissues, tumor margins, and adjacent normal tissues from a total of 80 patients with OSCC. We measured IL-17 expression by ELISA and performed hematoxylin and eosin (H&E) and immunohistochemical staining to evaluate the presentation of tumor budding and IL-17 expression in the TIF. IL-17 expression was significantly increased in the tumor tissues and margins compared with that in the normal tissues, which was confirmed by immunohistochemical staining. There were correlations between IL-17-positive tumor budding and T classification, lymph node metastasis, distant metastasis, clinical stage, and recurrence. In a multivariate survival analysis, the IL-17-positive tumor budding, besides tumor budding alone, was highly correlated with prognosis. Our results demonstrate a positive relationship between IL-17 expression and tumor budding in the OSCC TIF. IL-17 combined with tumor budding can serve as a valuable predictor of prognosis for patients with OSCC.

【 授权许可】

CC BY-NC